Share This Blog
Facebook
Top Posts
- North Carolina Golf Outing Raises Awareness of Carcinoid Cancer
- Two Lung Carcinoid Survivors Inspire and Lead the Way
- New OncLive TV Series Focuses on Neuroendocrine Tumors
- 5 Blogs and 2 Websites Recommended by the Carcinoid Cancer Foundation
- Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients
Archives
- June 2013 (1)
- May 2013 (2)
- April 2013 (1)
- March 2013 (4)
- February 2013 (3)
- January 2013 (4)
- December 2012 (7)
- November 2012 (3)
- October 2012 (1)
- September 2012 (1)
- August 2012 (3)
- July 2012 (3)
- June 2012 (2)
- May 2012 (3)
- April 2012 (3)
- March 2012 (3)
- February 2012 (3)
- January 2012 (3)
- December 2011 (4)
- November 2011 (4)
- October 2011 (2)
- September 2011 (1)
- August 2011 (6)
- July 2011 (5)
- June 2011 (6)
- May 2011 (3)
- April 2011 (5)
- March 2011 (4)
- February 2011 (1)
- January 2011 (11)
- December 2010 (1)
- November 2010 (6)
- October 2010 (6)
- September 2010 (6)
- August 2010 (6)
- July 2010 (6)
- June 2010 (6)
- May 2010 (8)
- April 2010 (9)
- March 2010 (12)
- February 2010 (11)
- January 2010 (12)
- December 2009 (4)
- November 2009 (1)
- October 2009 (3)
Blogroll
- whydotpharma explores how pharma companies can improve their patient focus via social media.
Carcinoid Cancer Foundation
- Carcinoid Cancer Foundation The premiere resource, nationally and internationally, for current and comprehensive carcinoid and neuroendocrine tumor information.
E-lists
Facebook
- CCF's Facebook Page Visit us on Facebook and meet others from the carcinoid/NET community.
Pharma Companies
Physicians
Resources
Support Groups
Survivor Stories
- http://www.carcinoid.org/content/survivor-stories Carcinoid/NET patients share their journeys through websites, blogs, and stories.
YouTube
- YouTube Visit our YouTube channel for videos featuring carcinoid/NET cancer specialists, patient perspectives, and conferences.
Twitter: @CarcinoidNETs
- #FF Thank you to very special #cancer advocates: @NETCancerDay, @RareDiseases, @askDR, @RareConnect, @drseisenberg, @myHEARTyrHANDS! 1 week ago
- Thank you Larry & Debbie Sanders & the staff & supporters of Arclin! Bringing about greater awareness of #carcinoid.. bit.ly/13LLCM1 1 week ago
- @myHEARTyrHANDS @AndreaNugent @kk760 @maggiewatts @rdassistmom @EileenTierno @PinkRibbons1995 Thanks so much! #FF 1 week ago
- Today is National Cancer Survivors Day! Celebrate those who have survived & support those newly diagnosed. #cancer ncsd.org 2 weeks ago
- Check out the #carcinoid awareness bracelets and zebra #MedicalAlert IDs at The Barking Zebra! thezebrashop.net 2 weeks ago
Tag Archives: Excel Diagnostics
First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. This is a Phase … Continue reading
Posted in carcinoid, carcinoid and neuroendocrine tumor treatments, clinical trials, neuroendocrine cancer
Tagged Advanced Accelerator Applications, carcinoid blogs, carcinoid clinical trials, carcinoid treatments, Dr. Ebrahim Delpassand, Ebrahim Delpassand, Erasmus Medical Center in Rotterdam, Excel Diagnostics, Excel Diagnostics & Nuclear Oncology Center, FDA and clinical trials, Food and Drug Administration, Lu-177 Octreotate, Lutathera, midgut carcinoid, midgut carcinoid and clinical trials, Molecular Nuclear Medicine, NETTER-1, neuroendocrine cancer clinical trials, Single Photon Emission Computer Tomography, somatostain analogs, SPECT, Susan Cork and Excel Diagnostics, theragnostics, Trojan horse in cancer therapy
Leave a comment
FDA Approves Amendment for PRRT Clinical Trial in Texas
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate in patients who have predominately liver metastasis … Continue reading
Posted in carcinoid, neuroendocrine cancer
Tagged Baylor College of Medicine, BioSnthema in Missouri, BioSynthema, BioSynthema Inc., carcinoid, carcinoid blogs, carcinoid cancer, carcinoid cancer clinical trials, carcinoid clinical trials, carcinoid treatments, Dr. Ebrahim Delpassand, Ebrahim Delpassand MD, Ebrahim S. Delpassand MD, Excel Diagnostics, Excel Diagnostics & Nuclear Oncology Center, FDA and carcinoid, FDA and Lu177, FDA and neuroendocrine cancer, Food and Drug Administration, Inc., Inc. of St. Louis, LU 177, LU-177 with Octreotate, Lu-177 with Octreotate clinical trial, neuroendocrine cancer, neuroendocrine cancer clinical trials, neuroendocrine cancer treatments, neuroendocrine tumor treatments, neuroendocrine tumors, peptide receptor radionuclide therapy, PRRT, PRRT clinical trial, PRRT in the United States, PRRT trial, Radioisotope Therapy of America (RITA) Foundation, RITA Foundation, St. Luke's Episcopal Hospital in Houston, Susan Cork, U.S. Food and Drug Administration, Y-90, yttrium 90
1 Comment
10 Highlights of the Year 2011 for the Carcinoid and Neuroendocrine Tumor Community
As the Carcinoid Cancer Foundation looks back on the year 2011, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community. Here are 10 of the year’s important stories: 1) The FDA approved the first … Continue reading
Posted in carcinoid, carcinoid awareness, neuroendocrine cancer awareness, neuroendocrine tumors
Tagged 2011 ASCO Expressions of Hope Calendar, 2011 Expressions of Hope calendar, 2011 Warner Advocacy Award, Adria Di Maria, Afinitor, ASCO, ASCO Expressions of Hope Calendar, Bad Berka, carcinoid awareness, Carcinoid Cancer Awareness Network, Carcinoid Cancer Foundation, Carcinoid Car, carcinoid conferences, carcinoid patient advocacy, CCAN, Dr. Richard Baum, Ebrahim Delpassand, everolimus, Excel Diagnostics, Expressions of Hope calendar, Frank Rosch, Frank Rosch and University of Manz, Gallium 68, InterScience Institute, iWalk, iWalk for Carcinoid, Marlena Johnston, Monica Warner, NANETS, NASCAR, NASCAR Sponsafier 4, NET Alliance, NET Cancer Day, North American NeuroEndocrine Tumor Society, Novartis, Novartis Oncology, Novartis Pharmaceuticals, Novartis Pharmaceuticals Corporation, paintings by Adria Di Maria, PRRT, PRRT at Bad Berka, PRRT clinical trial, Richard Baum, Steve Jobs, Steve Jobs cancer, Steve Jobs carcinoid, Steve Jobs pancreatic cancer, Steve Jobs pancreatic neuroendocrine tumor, sunitinib, Sutent, The Song Bird Keeps Singing by Adria Di Maria, The Song Bird Keeps Singing painting, theranostics, Warner Advocacy Award, world congress on Gallium 68 and PRRT, Worldwide NET Cancer Awareness Day, Zentralklinik Bad Berka
1 Comment
Worldwide NET Cancer Awareness Day Update: Events from Australia to Europe to North America
Go around the globe for the second Worldwide NET Cancer Awareness Day (WNCAD) on November 10, 2011. Throughout that day, videos featuring NET events and experts will air on http://www.netcancerday.org as the sun travels west, from Australia to Europe to … Continue reading
Posted in WNCAD, Worldwide NET Awareness Day, Worldwide NET Cancer Awareness Day
Tagged Alexandria Phan, APOZ & Friends, APTED, Carcinoid and Neuroendocrine Tumor Society of Canada, carcinoid blogs, Carcinoid Cancer Awareness Network, Carcinoid Cancer Foundation, carcinoid conferences, CarciNor, Caring for Carcinoid Foundation, CARPA, CNETS Canada, Dr. Alexandria Phan, Dr. Ebrahim Delpassand, Dr. Eric Liu, Dr. James Yao, Dr. Jason Fleming, Dr. Thomas Aloia, Ebrahim Delpassand, Excel Diagnostics, Hope Society for Cancer Care, James Yao, MD Anderson, MD Anderson Cancer Center, NET cancer, NET Cancer Awareness Day, NET cancer conferences, NET Cancer Day, NET Cancer Day on Facebook, NET Cancer Day on Twitter, NET Patient Foundation, Netzwerk Neuroendokrine Tumoren (NeT) e. V., neuroendocrine tumors, pancreatic neuroendocrine cancer, pancreatic neuroendocrine tumors, rare cancers, rare diseases, Stichting NET-groep, Strides for Stripes awareness walk, The Unicorn Foundation, University of Texas MD Anderson Cancer Center, walks for NET cancer awareness, Worldwide NET Cancer Awareness Day
1 Comment
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim S. … Continue reading
Posted in carcinoid, neuroendocrine tumors, nuclear imaging, clinical trials, carcinoid and neuroendocrine tumor treatments, carcinoid specialists, NET (neuroendocrine tumor) cancer, neuroendocrine cancer
Tagged American College of Nuclear Medicine, Baylor College of Medicine, carcinoid blogs, Carcinoid Cancer Foundation, carcinoid treatments, clinical trials for carcinoid, Dr. Ebrahim Delpassand, Dr. Richard Warner, Ebrahim Delpassand MD, Excel Diagnostics, Excel Diagnostics Imaging Clinic, FDA, FDA and Lu177, Food and Drug Administration, Ga-68, Gallium 68, Gallium-68 Octreotide PET scan, GlucoMedix, Governor Rick Perry, NET cancer, NET cancer blogs, neuroendocrine cancer, neuroendocrine tumor treatments, nuclear imaging, nuclear imaging tests for carcinoid patients, Octreotide PET scans, peptide receptor radionuclide therapy, PET scans, PRRT, PRRT trial, Radioisotope Therapy of America (RITA) Foundation, RadioMedix, Richard R.P. Warner, Richard Warner, RITA Foundation, SyntheMedix, Texas Emerging Technology Fund
Leave a comment
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of Excel Diagnostics, has announced that … Continue reading
Posted in carcinoid, carcinoid and neuroendocrine tumor treatments, carcinoid doctors, carcinoid specialists, NET (neuroendocrine tumor) cancer, neuroendocrine cancer, neuroendocrine tumors, nuclear imaging, rare cancers, rare diseases, Uncategorized
Tagged Baylor College of Medicine, Carcinoid Cancer Foundation, carcinoid clinical trials, carcinoid treatments, Christiane Assir, clinical trials, Dik J. Kwekkeboom, Dr. Ebrahim Delpassand, Dr. Richard Warner, Ebrahim S. Delpassand MD, Erasmus Medical Center, Eric Krenning, Excel Diagnostics, Excel Diagnostics Imaging Clinics, FDA, Food and Drug Administration, LU 177, LU-177 with Octreotate, Lutetium 177, M.D. Anderson Cancer Center, Mount Sinai Center for Carcinoid and Neuroendocrine Tumors, Mount Sinai Hospital, neuroendocrine cancer clinical trials, nuclear medicine, nuclear medicine therapy, peptide receptor radionuclide therapy, pheochromocytoma, Radio-Isotope Therapy of America (RITA) Foundation, radio-peptide targeted therapy, Richard R.P. Warner, Richard Warner, RITA Foundation, U.S. Food and Drug Administration, Y-90
19 Comments
